Remove Insulin Remove Packaging Remove Trials
article thumbnail

Roche debuts smart glucose monitor for hospital use

pharmaphorum

.” The Android-powered device can run certified third-party software, initially shipping with a handful of apps including Glytec’s Glucommander insulin-dosing software under the terms of a deal announced today.

Insulin 128
article thumbnail

MIOTIFY platform for digital health products clears AZ road test

pharmaphorum

UK company MIOTIFY has developed a web-based software platform that product teams can use to configure medical algorithms quickly, create code packages to harness them and generate supporting documentation – all in a format that is designed to meet regulatory requirements for software as a medical device (SaMD). Sheena Macpherson.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A USD 4.2 Billion Myovant/ Pfizer Deal; Audentes Therapeutics’ ASPIRO Trial Free to Proceed; First Generic of Drug for Severe Hypoglycemia Gets Approval; Teleflex Acquires Z-Medica

Delveinsight

Audentes Therapeutics’ ASPIRO Trial Free to Proceed. The Food and Drug Administration (FDA) decided to lift the clinical ban from Audentes Therapeutics’ ASPIRO trial, which was aimed at investigating its AT132 for the treatment of X-linked myotubular myopathy (XLMTM), a rare neuromuscular disease. . The post A USD 4.2

Trials 52
article thumbnail

Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics

XTalks

In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 percent in the US, impacted by prior formulary losses as well as “erosion of the basal insulin market,” the company said in the statement. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6

Sales 52
article thumbnail

GLP1 Receptor Agonist Market: Current Landscape, Growth Opportunities and Future Market Outlook

Roots Analysis

per package in the US. Growing Interclass Drug Competition: The diabetes treatment market is highly competitive, comprising of various alternative therapies (including oral anti-diabetics, insulin, and other injectable medications); notably, the introduction of biosimilars is likely to impact the dynamics of this market.

article thumbnail

Tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes

The Pharma Data

SURPASS-2 was a 40-week, randomized, open-label trial comparing the efficacy and safety of tirzepatide to semaglutide as an add-on to metformin in adults with type 2 diabetes. Lilly intends to submit the full registration package to regulatory authorities by the end of 2021. The trial randomized 1,879 study participants across the U.S.,

article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. Other drugs also contributed to Merck’s revenue growth.

Sales 98